Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
Despite growing awareness of the role of newer anti-VEGF agents in the management of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), retina specialists may still face challenges in extending patients’ treatment intervals with these agents.
Because the use of these agents may be influenced by practice infrastructure, clinician perception, and payer environment, a panel of retina specialists in California participated in a focus group to discuss clinical hurdles they encounter in daily practice. These ranged from logistical and patient-level barriers to broader workflow or institutional constraints. In this continuing medical education program, the moderator of the focus group will provide insights into the topics, challenges, and solutions that arose during this meeting.
Target Audience
This online educational activity is directed toward ophthalmologists, optometrists, and other eye care professionals involved in the management of patients with neovascular retinal diseases.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Recognize region-specific barriers to the implementation of neovascular retinal disease management and strategies for overcoming them in clinical practice.
- Integrate advanced anti-VEGF therapies into personalized treatment plans based on local patient and workflow needs in nAMD
- Integrate advanced anti-VEGF therapies into personalized treatment plans based on local patient and workflow needs in DME
- Integrate advanced anti-VEGF therapies into personalized treatment plans based on local patient and workflow needs in RVO
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here